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Background: Chronic gastritis, peptic ulcer disease, and gastric cancer have been shown to be related to infection
with Helicobacter pylori (H. pylori). Two major virulence factors of H. pylori, CagA and VacA, have been associated
with these sequelae of the infection. In this study, total DNA was isolated from gastric biopsy specimens to assess
the cagA and vacA genotypes.
Results: Variations in H. pylori cagA EPIYA motifs and the mosaic structure of vacA s/m/i/d regions were analysed in
155 H. pylori-positive gastric biopsies from 71 individuals using PCR and sequencing. Analysis of a possible
association between cagA and vacA genotypes and gastroduodenal pathogenesis was made by logistic regression
analysis. We found that H. pylori strains with variation in the number of cagA EPIYA motif variants present in the
same biopsy correlated with peptic ulcer, while occurrence of two or more EPIYA-C motifs was associated with
atrophy in the gastric mucosa. No statistically significant relation between vacA genotypes and gastroduodenal
pathogenesis was observed.
Conclusions: The results of this study indicate that cagA genotypes may be important determinants in the development
of gastroduodenal sequelae of H. pylori infection. In contrast to other studies, vacA genotypes were not related to disease
progression or outcome. In order to fully understand the relations between cagA, vacA and gastroduodenal pathogenesis,
the mechanisms by which CagA and VacA act and interact need to be further investigated.
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structureBackground
H. pylori is a microaerophilic, spiral shaped Gram-negative
bacterium that chronically infects the gastric mucosa [1]. It
is recognised as a human pathogen associated with chronic
gastritis [1], peptic ulcer [2] and gastric cancer [3], the
development of which are related to the virulence factors
cytotoxin associated antigen (CagA) [4,5] and vacuolating
cytotoxin A (vacA) [6,7]. It has been reported that CagA
and VacA polymorphisms are associated with distinct
pathological features in H. pylori infected adults with
gastrointestinal diseases [8-14].* Correspondence: hans-jurg.monstein@liu.se
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reproduction in any medium, provided the orCagA has emerged as a major virulence factor for
gastroduodenal disease severity, including an increased
cancer risk [9,15]. CagA is injected into epithelial cells
mediated by a type IV secretion system [4,16,17]. In the
host cell, CagA localises to the inner surface of the
plasma membrane and becomes phosphorylated on
specific tyrosine residues within repeating penta amino
acid Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs present at the
C-terminus of the protein [18-20]. This part of the
protein is encoded by the variable 3’-region of the cagA
gene [4,5,21,22] (Figure 1). Four different cagA EPIYA
motifs have been defined according to the amino acid
sequence that surrounds the EPIYA residues; EPIYA-A, -B,
-C and -D [20,22-25]. CagA toxins nearly always possess
EPIYA-A and EPIYA-B, followed by varying numbers of
EPIYA-C in Western-type isolates [22]. In East Asian-type
of clinical H. pylori isolates, EPIYA-A and -B are, on thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A) Schematic illustration of the H. pylori 26695 cagA gene. M13-CagA.epiya.se and T7-CagA.epiya.as indicate the position of the
primers used in PCR amplification. B) Amino acids flanking the EPIYA motifs present in EPIYA-A, EPIYA-B, and EPIYA-C segments of H. pylori 26695.
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[24,25]. It has been suggested that the considerable
variation in number of repeating EPIYA-C motifs at the
C-terminus of the protein may alter the biological ac-
tivity of CagA in phosphorylation-dependent as well
as phosphorylation-independent ways [20,26]. It was
suggested that the number of cagA EPIYA-C motifs
and the tyrosine phosphorylation status of CagA are
important risk factors for gastric cancer among Western
strains [27]. This is also supported by a higher risk of
cancer development in strains with a high degree of
phosphorylation [28].
VacA induces vacuolisation in gastric epithelial cells
by attaching to the cell membrane [29]. It also induces
apoptosis in these cells via the mitochondrial pathway
[30-33]. Initially, DNA sequence analysis revealed that
the VacA protein has a mosaic structure comprising allelic
variations in the signal (s) and mid region (m) (Figure 2),
each having two different alleles (s1/s2, m1/m2) with dif-
ferent biological activities [6,34]. The s and m regions have
been associated with gastric cancer and the premalignant
condition gastric mucosal atrophy [35,36]. Recently, it was
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Figure 2 Schematic illustration of the H. pylori 26695 vacA gene. The
deletion-region (DR) and mid region (MR) and the primers used (Table 2) a
sequenced.the s and m regions (Figure 2), is associated with gastric
cancer [27,37-40]. Similarly, a novel vacA gene deletion
(d) region (Figure 2) has been described [36]. The d region
is located between the vacA i and m regions, and involves
a cleavage site crucial for the protein function and is asso-
ciated with gastroduodenal diseases [36]. Amino-acid
alterations in the repeated hydrophilic motif region
(RHM), largely overlapping the d region of vacA, were
previously shown not to be associated with any specific
gastroduodenal disease [41].
H. pylori cagA and vacA gene polymorphisms are well
studied and it is assumed that these polymorphisms,
alone or in concert, are associated in H. pylori associated
pathogenesis [9,10,13,42,43]. However, some studies
have reported a lack of association between H. pylori
cagA and vacA gene polymorphisms and the severity or
progression of H. pylori associated diseases [25,44].
Statistical outcome is dependent on the population stud-
ied. We aimed to analyse a randomly selected population
in South-eastern Sweden with regard to H. pylori cagA
and vacA genotypes and sequelae using logistic regression
analysis. By means of a previously described PCR-based
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Figure 3 Summary of the various cagA EPIYA motif
combinations based on amplicon sequencing. The large number
of genotypes presented is due to biopsies having several motif
combinations (multiple amplicons). For full information about EPIYA
motifs in each biopsy, see Additional file 1. N = number of strains.
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isolated from 155 fresh frozen (−80°C) gastric biopsy
specimens.
Results
Presence of H. pylori DNA in the gastric biopsy specimens
Using MDA-DNA and 16S rDNA variables V3 region
pyrosequencing analysis, the presence of H. pylori-DNA
in all 155 biopsy specimens was confirmed.
Analysis of cagA EPIYA motifs
A total of 155 gastric biopsy specimens from 71 individuals
were analysed for cagA EPIYA genotypes. In 92 biopsy
specimens a single cagA amplicon was detected. DNA
sequencing revealed the presence of different cagA EPIYA
genotypes: EPIYA-AB in two, ABC in 56, ABCC in 29, and
ABCCC, AC, ACC, AABC, AABCC in one biopsy each
(Figure 3). In 37 biopsy specimens positive for the cagA
EPIYA motif, two or more cagA amplicons were detected.
Of these 37 specimens, the majority (19 specimens) were
mixes between ABC and ABCC (Additional file 1). From
26 biopsy DNA samples, no cagA EPIYA motif amplicons
could be generated.
Statistical analysis revealed that H. pylori strains with
different number of cagA EPIYA motif variants present
in the same biopsy was correlated to peptic ulcer devel-
opment, OR = 2.77 (1.10-7.00). In the present study,
peptic ulcer included four cases of duodenal ulcers,
three pre-pyloric ulcers, two gastric ulcers and five
cases of previously diagnosed ulcers of undefined origin
(no data available).
Two or more cagA EPIYA-C motifs were associated with
development of gastric atrophy, OR = 1.86 (1.05-3.30). In
biopsies with mixed amplicons, the number of EPIYA-C
was determined from the amplicon with the highest
number of repeats. Gastritis was histologically classified
according to the Sydney system, and atrophy of the gastric
mucosa was graded from 1–3 (1 = mild, 2 = moderate,
3 = severe) [47]. For the purpose of the present study,
moderate to severe atrophy of the gastric mucosa was
classified as atrophic gastritis.
Statistical calculations were performed also in subgroups
based on the location in the stomach (corpus, antrum). No
differences were observed between the groups regarding
their respective disease progression.
Analysis of cagE and cag-PAI empty-site
To detect deletions of cagA within cagPAI, a region
surrounding cagA (cag-PAI empty site) was amplified, as
well as the cagE gene (also located within the cag-PAI).
Amplification of cagE was successful in 114 of the biopsies.
Of the remaining 41 biopsies, only 19 successfully amplified
the cag-PAI empty site region, indicating the presence of
mutated primer target sites or absence of cagE.Analysis of vacA s/i/d/m-region
Four regions of the vacA gene (s, m, i and d regions)
were genotyped. PCR amplification and DNA sequence
analysis in 155H. pylori positive biopsy specimens
revealed full information from all regions of vacA in 146
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majority were of s1a (130) or s1b (19) genotype, while
only three samples were s2 genotype. In the m region
the distribution was more even, with 87 samples of m1
genotype and 64 samples of m2 genotype. DNA from 32
of the biopsies displayed a deletion of the d region (d2),
while 115 isolates showed wild-type sequence (d1) in this
region. The intermediate region is classified according to
two different sequences, and may be of i1, i2, i1-i2 or i2-i1
genotype. In this material, 94 isolates were of i1 genotype,
24 isolates of i2 genotype and 31 isolates of i2-i1 genotype.
None were of i1-i2 type.
The genotypes of these regions were divided into three
groups (Figure 4); group 1 contained 83 isolates of s1-d1-
m1 genotype (regardless of i region), group 2 contained 30
isolates that were of d1-m2 genotypes (regardless of the s
and i regions), and group 3 contained 32 isolates that were
of d2 genotype (regardless of all other regions). Isolates that
were indeterminate in one or more regions (n = 9) were
excluded from this compilation.
In group 3, there were two isolates (6%) derived from
peptic ulcer patients, while in group 1 and 2 there were
20 isolates (24%) and eight isolates (27%), respectively,
originating from ulcer patients. The lower frequency of
peptic ulcer observed in vacA s1d1m1 genotype com-
pared to other genotypes was not statistically significant.
Eight biopsies from group 1 (10%) and two biopsies from
group 2 (7%) were derived from patients with atrophic
gastritis, while in group three there was no subject with
atrophic gastritis (not statistically significant).
Intraindividual variations of cagA EPIYA and vacA
genotypes in corpus, antrum and duodenal bulb
In 51 of 71 individuals, biopsy specimens from all three
locations of the stomach (corpus, antrum and duodenal
bulb) were available for analysis. In 26 of these 51
subjects, the cagA and vacA genotypes were identical in
all locations. Considering the remaining 25 subjects, 22
subjects differed with respect to the cagA EPIYA genotype,
two with regard to the vacA (i) genotype, two considering
the vacA (d) genotype and one with respect to the vacA
(m) genotype, when comparing the locations for each
subject (Additional file 1).i1/i2-i1/i2s1a/s1b/s2 d2
i1/i2-i1s1a/s1b d1
i1/i2-i1/i2s1a/s1b/s2 d1
Figure 4 Summary of the vacA gene mosaic combinations based on a
14 biopsies could not be established. N = number of strains; s1/s2, signal-se
m1/m2 =mid-region type.Discussion
The results of several studies have indicated that there is
an association between the cagA gene and gastric cancer
[14,27,28,48]. There are also reports showing an associ-
ation between the vacA gene and gastroduodenal sequelae
(e.g. peptic ulcer, atrophic gastritis) of H. pylori infection
[36,38-40].
Here we show that of the individuals with biopsies
from all locationsns (corpus, antrum and duodenal
bulb), 49% had different cagA EPIYA genotype between
the three locations. There is a possibility that these indi-
viduals may have been infected with different strains on
different occasions. However, it is perhaps more likely
those H. pylori strains acquired genetic alterations in
cagA after infection. Three recombination mechanisms
have been detected in the cagA gene; homologous
recombination between CM sequences, recombination
between EPIYA sequences or between short similar
sequences [49]. These recombination mechanisms, as
well as mutations in the gene, may serve as a driving
force for generating strain diversity in H. pylori, also
called microevolution [50]. It is possible that infection
with multiple H. pylori ancestral strains or alternatively,
a single ancestral strain undergoing microevolution in
the cagA gene giving rise to H. pylori subclones with
different cagA EPIYA motif variants in the same biopsy
specimen, may be more aggressive than a single ances-
tral strains acting alone. In an early study it has been
suggested that the majority of Swedish clinical isolates of
H. pylori from patients of higher age (>63 years old)
represent single strain infections. However, in younger
ages multiple strain infection may be more common
[51]. Furthermore, it has been discussed that different
subclones of each strain, some of which might be cagA-
positive or -negative, may coexist, possibly colonising
different areas of the stomach during different periods of
life-long H pylori infection [51]. In this context, the aim
of this study was to investigate a possible association
between the presence of H. pylori cagA EPIYA motifs
and disease outcome. We found an association between
H. pylori DNA isolated from the same biopsy specimen
and generating two or more cagA EPIYA motif variant
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Corpus Antrum Duodenal bulb
ABC 34 34 34
AC 14 14
AB - 2 2
BC 1 - 1
C 12 - -
A - 7 -
71 61 57 37
1A, Antrum; B, Duodenal bulb; C, Corpus.
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EPIYA-C motifs in the cagA gene of the biopsy (corpus and
antrum only) H. pylori strains, OR = 1.86 (1.05-3.30). Previ-
ous studies have also found this correlation [14,27] and it
has been suggested that a higher number of EPIYA-C
motifs enables a higher degree of phosphorylation, and,
hence, increases the risk of gastric cancer and gastric intes-
tinal metaplasia [28]. One explanatory mechanism in this
aspect may be the interaction of CagA with the protein
ASPP2, which normally activates p53 to induce apoptosis.
CagA inhibits ASPP2, leading to an increased cell survival
and enhanced transformation of the cell [48].
Other studies have shown an association of gastric
cancer and atrophy to the s1 genotype [35], the s1m1
genotype [36], or the i1 genotype [27,37-39]. In the
present study, we detected a higher frequency of atrophy
among the vacA s1d1m1 genotype than among other
genotypes. However, none of these results were statistically
significant, which could be due to small or unevenly
distributed groups of samples (type II error).
Miernyk and co-workers observed an increased risk of
developing peptic ulcer disease in s1m1 compared toTable 2 Primers used for PCR amplification in the study
Amplicon Primer 5' > 3' 1
VacA (s) M13-SeqS.SE CGTTGTAAAACGACGG
SeqS.AS CCCARCCTCCATCAAT
VacA (i + d) M13-SeqVac.SE CGTTGTAAAACGACGG
SeqVac.AS CGCTTGATTGGACAG








1italic letters, universal tag sequence.s1m2/s2m2 vacA genotype [52]. Our study shows a
tendency towards a similar association, although not
statistically significant.
Conclusions
In summary, H. pylori strains with variation in the number
of cagA EPIYA motif variants present in the same biopsy
were associated with the occurrence of peptic ulcer. Simi-
larly, two or more EPIYA-C motifs were associated with
atrophy in the gastric mucosa. No statistically significant
association between vacA genotypes and gastroduodenal
pathogenesis was observed.
Methods
Study subjects and tissue collection
Frozen (−80°C) gastric biopsy specimens from a gastro-
scopic re-screening study in a randomly selected cohort
of the population of Linköping, County of Östergötland,
South-eastern Sweden, were used [53]. The study was
approved by the local ethics committee in Linköping,
Sweden (Dnr. 98007) and conducted in accordance with
the Helsinki declaration. In the clinical setting, H. pylori
status was classified as positive when more than one of
the following occurred: H. pylori identified by light
microscopic examination; a positive urease test on fresh
biopsy specimen; an elevated level of H. pylori IgG
antibodies in serum. Microscopic examination was
performed by a single experienced pathologist who was
blinded to the other data. Kappa analysis of the blinded
repeat evaluation of the Sydney system scores of the
biopsy sections from the antrum and corpus has been
described by Redéen and co- workers [47]. From this co-
hort, a total of 155 biopsy specimens (61 corpus, 57 an-
trum and 37 from the duodenal bulb) from 71
individuals fulfilling the criteria for presence of H. pylori
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were available (Table 1).
DNA was isolated from the homogenized tissue using
an automated nucleic extractor M48 and MagAttract
DNA Mini M48 kit following the manufacturer’s instruc-
tion (Qiagen, Hilden, Germany). The isolated DNA was
enriched by whole genome amplification by means of mul-
tiple displacement amplification (MDA), using an Illustra
GenomiPhi V2 DNA kit (GE-Healthcare, Uppsala, Sweden)
according to standard protocols.
PCR amplification
Initially, the presence H. pylori DNA in the biopsy
specimens were verified using 16S rDNA V3 region
pyrosequencing analysis [54].
The cagA EPIYA motifs, located in the 3’-half of the cagA
gene (Figure 1), were amplified using primer M13-CagA.
EPIYA.SE and T7-CagA.EPIYA.AS (Figure 1; Table 2) The
cagE gene and the cagA Pathogenicity Island (cag-PAI)
empty site were amplified using primer M13-CagE.SE
and CagE.AS, and primers M13(−21)_2.SE and T7_25.
AS (Table 2), respectively.
VacA s/i/d/m region subtyping was accomplished by
three single PCR amplification assays. The signal-sequence
(SS) region was amplified using primer M13-SeqS.se and
SeqS.as; the intermediate and deletion region (IR and DR)
using primer M13-SeqVac.se and SeqVac.as; the midregion
(MR) using primer M13-SeqM.se and VAG-R (Figure 2;
Table 2), respectively
Amplification conditions used were identical in all
assays as described previously [45]. Prior to sequencing,
amplicons were analysed by automated capillary gel elec-
trophoresis using a QIAxcel system and a QIAxcel DNA
High Resolution kit (Qiagen, Hilden, Germany).
cagA EPIYA motif and vacA s/i/d/m-region sequence
analysis
M13-tagged cagA EPIYA and vacA amplicons were
sequenced using M13 uni (−21) sequencing primer and
a customer sequencing service (Eurofins MWG Operon,
Ebersberg, Germany). The obtained cagA and vacA
sequences were aligned and compared with catalogued
H. pylori 26695 [GenBank:AE000511, H. pylori J99
[GenBank:AE001439], H. pylori P12 [GeneBank:CP001217],
H. pylori G27 [GenBank:CP001173], and H. pylori Shi470
[GeneBank:CP001072] sequences using the CLC DNA
Workbench version 5.5 [55]. Sequences were retrieved from
the NCBI nucleotide database [56]. CagE and cag-PAI
(empty-site) amplicon sizes were analysed by capillary gel
electrophoresis only.
Statistical analysis
Binary logistic regression analysis of data was performed
using Minitab 15 software. Statistical significance wasassumed at P < 0.05. All statistical analyses presented
here were significant according to Hosmer-Lemeshow
(HL) goodness-of-fit test, with HL p values >0.05. In the
logistic regression analysis and the GLM analysis, a 95%
confidence interval including 1.0 was regarded as non-
significant. Odds ratios with 95% confidence intervals
(CI) were calculated to explore possible associations of
individual genotypes to peptic ulcer or gastric atrophy.
Age and sex were included as covariates. With regard to
atrophy, data from duodenal biopsies were not included
in the statistical analysis.
Additional file
Additional file 1: Results from cagA and vacA genotyping,
including clinical data.
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